Format

Send to

Choose Destination
See comment in PubMed Commons below
Neuro Oncol. 2013 Jun;15(6):783-7. doi: 10.1093/neuonc/not021. Epub 2013 Mar 3.

A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood.

Author information

1
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bloomberg 11379, 1800 Orleans St, Baltimore, MD 21287, USA. kcohen@jhmi.edu

Abstract

BACKGROUND:

Arsenic trioxide (ATO) has demonstrated preclinical evidence of activity in the treatment of infiltrating astrocytomas.

METHODS:

We conducted a phase I trial of ATO given concomitantly with radiation therapy in children with newly diagnosed anaplastic astrocytoma, glioblastoma, or diffuse intrinsic pontine glioma. Eligible patients received a fixed daily dose of 0.15 mg/kg of ATO once a week, with each subsequent cohort of patients receiving an additional dose per week up to a planned frequency of ATO administration 5 days per week as tolerated. Twenty-four children were enrolled and 21 children were evaluable.

RESULTS:

ATO was well tolerated throughout the entire dose escalation, resulting in confirmation of safety when administered 5 days per week during irradiation.

CONCLUSIONS:

The recommended dose of ATO during conventional irradiation is 0.15 mg/kg given on a daily basis with each fraction of radiation therapy administered.

KEYWORDS:

arsenic trioxide; astrocytoma; chemoradiotherapy; pediatrics

PMID:
23460318
PMCID:
PMC3661102
DOI:
10.1093/neuonc/not021
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems Icon for PubMed Central
    Loading ...
    Support Center